| Name | Title | Contact Details |
|---|
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
Innovative, Anatomic Solutions
Unlocking the health benefits of cannabinoids. Learn More Unlocking the health benefits on cannabinoidsLearn more We are a team of medical experts. Meet our team https://sanitygroup.com/wp-content/uploads/2020/11/SP_Homepage_Video_Compressed_BW.mp4 Med...
NLI offers: , Drug cGMP quality manufacturing processes , Superior laboratory support services following current Good Manufacturing Practices (cGMPs) , Disciplined and documented product design and engineering systems , Information-based customer
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.